Evaluation of efficacy and safety profile of posaconazole for prophylaxis after allogeneic haematopoietic stem cell transplant

被引：0
|
作者：
Silva, F. [1 ]
Vazquez, L. [1 ]
Morales, E. [1 ]
Caballero, D. [1 ]
Perez-Simon, J. A. [1 ]
Sanchez-Guijo, F. [1 ]
del Canizo, C. [1 ]
Miguel, J. San [1 ]
机构：
[1] Hosp Univ Salamanca, Salamanca, Spain
来源：
BONE MARROW TRANSPLANTATION | 2009年 / 43卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S370 / S370
页数：1
相关论文
共 50 条
  • [21] Efficacy of darbopoietin alfa after allogeneic haematopoietic stem cell transplantation
    Picardi, A
    Spagnoli, A
    Tendas, A
    Mirabile, M
    Cudillo, L
    Dentamaro, T
    Suppo, G
    Amadori, S
    de Fabritiis, P
    BONE MARROW TRANSPLANTATION, 2005, 35 : S103 - S103
  • [22] CMV prophylaxis following allogeneic haematopoietic stem cell transplant: a single-centre review
    Jealous, Z. E.
    Collins, A.
    Crawley, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 103 - 103
  • [23] Efficacy, Safety, and Breakthrough Infections Associated with Standard Long-Term Posaconazole Antifungal Prophylaxis in Allogeneic Stem Cell Transplantation Recipients
    Winston, Drew J.
    Bartoni, Kathy
    Territo, Mary C.
    Schiller, Gary J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (04) : 507 - 515
  • [24] Posaconazole is superior to itraconazole for antifungal prophylaxis in allogeneic stem cell transplant recipients:: a single-centre experience
    Arnan, M.
    Patino, B.
    Peralta, T.
    Gudiol, C.
    Parody, R.
    de Sevilla, A. Fernandez
    Duarte, R. F.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S272 - S273
  • [25] Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients
    M. Mikulska
    V. Del Bono
    P. Bruzzi
    A. M. Raiola
    F. Gualandi
    M. T. Van Lint
    A. Bacigalupo
    C. Viscoli
    Infection, 2012, 40 : 271 - 278
  • [26] Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients
    Mikulska, M.
    Del Bono, V.
    Bruzzi, P.
    Raiola, A. M.
    Gualandi, F.
    Van Lint, M. T.
    Bacigalupo, A.
    Viscoli, C.
    INFECTION, 2012, 40 (03) : 271 - 278
  • [27] Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients
    Greco, R.
    Barbanti, M. C.
    Stanghellini, M. T. Lupo
    Giglio, F.
    Morelli, M.
    Messina, C.
    Forcina, A.
    Oltolini, C.
    Piemontese, S.
    Scarpellini, P.
    Marktel, S.
    Assanelli, A.
    Carrabba, M.
    Vago, L.
    Corti, C.
    Bernardi, M.
    Peccatori, J.
    Ciceri, F.
    BONE MARROW TRANSPLANTATION, 2016, 51 (07) : 1022 - 1024
  • [28] Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients
    R Greco
    M C Barbanti
    MT Lupo Stranghellini
    F Giglio
    M Morelli
    C Messina
    A Forcina
    C Oltolini
    S Piemontese
    P Scarpellini
    S Marktel
    A Assanelli
    M Carrabba
    L Vago
    C Corti
    M Bernardi
    J Peccatori
    F Ciceri
    Bone Marrow Transplantation, 2016, 51 : 1022 - 1024
  • [29] Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients
    Bruggemann, Roger J. M.
    Blijlevens, N. M. A.
    Burger, David M.
    Franke, Barbara
    Troke, Peter F.
    Donnelly, J. Peter
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (01) : 107 - 113
  • [30] Epidemiology of cytomegalovirus in allogeneic haematopoietic stem cell transplant recipients
    Moya, R
    Espigado, I
    De la cámara, R
    Rovira, M
    Jarque, I
    Julia, A
    Valera, B
    Herreros, JMC
    BONE MARROW TRANSPLANTATION, 2006, 37 : S183 - S183
12345